CN118077774A - Formula milk powder capable of improving mineral absorption and preparation method thereof - Google Patents
Formula milk powder capable of improving mineral absorption and preparation method thereof Download PDFInfo
- Publication number
- CN118077774A CN118077774A CN202410335101.8A CN202410335101A CN118077774A CN 118077774 A CN118077774 A CN 118077774A CN 202410335101 A CN202410335101 A CN 202410335101A CN 118077774 A CN118077774 A CN 118077774A
- Authority
- CN
- China
- Prior art keywords
- formula
- vitamin
- alpha
- casein
- lactalbumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 159
- 239000000843 powder Substances 0.000 title claims abstract description 127
- 239000011707 mineral Substances 0.000 title claims abstract description 84
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 83
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 102000011632 Caseins Human genes 0.000 claims abstract description 116
- 108010076119 Caseins Proteins 0.000 claims abstract description 116
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 112
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 112
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 112
- 235000021247 β-casein Nutrition 0.000 claims abstract description 110
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 98
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960002477 riboflavin Drugs 0.000 claims abstract description 63
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 60
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 60
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 235000013336 milk Nutrition 0.000 claims abstract description 40
- 239000008267 milk Substances 0.000 claims abstract description 40
- 210000004080 milk Anatomy 0.000 claims abstract description 40
- 235000010755 mineral Nutrition 0.000 claims description 82
- 235000016709 nutrition Nutrition 0.000 claims description 45
- 239000002994 raw material Substances 0.000 claims description 44
- 230000035764 nutrition Effects 0.000 claims description 38
- 239000011575 calcium Substances 0.000 claims description 34
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 33
- 229910052791 calcium Inorganic materials 0.000 claims description 33
- 239000011777 magnesium Substances 0.000 claims description 31
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 29
- 229910052749 magnesium Inorganic materials 0.000 claims description 29
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 28
- 239000011701 zinc Substances 0.000 claims description 28
- 229910052725 zinc Inorganic materials 0.000 claims description 28
- 230000001965 increasing effect Effects 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 24
- 230000001954 sterilising effect Effects 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 23
- 108010078791 Carrier Proteins Proteins 0.000 claims description 22
- 235000015097 nutrients Nutrition 0.000 claims description 19
- 238000001816 cooling Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 16
- 241000186000 Bifidobacterium Species 0.000 claims description 14
- 101001120710 Homo sapiens Ovarian cancer G-protein coupled receptor 1 Proteins 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- 102100026070 Ovarian cancer G-protein coupled receptor 1 Human genes 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 102000003567 TRPV4 Human genes 0.000 claims description 14
- 101150098315 TRPV4 gene Proteins 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- -1 compound vitamin Chemical class 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 102000010445 Lactoferrin Human genes 0.000 claims description 10
- 108010063045 Lactoferrin Proteins 0.000 claims description 10
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 10
- 235000021242 lactoferrin Nutrition 0.000 claims description 10
- 229940078795 lactoferrin Drugs 0.000 claims description 10
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 235000020183 skimmed milk Nutrition 0.000 claims description 9
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 8
- 235000019743 Choline chloride Nutrition 0.000 claims description 8
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 8
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 8
- 229960003178 choline chloride Drugs 0.000 claims description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 235000021119 whey protein Nutrition 0.000 claims description 7
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 238000007580 dry-mixing Methods 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000020209 toddler milk formula Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 239000003921 oil Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 31
- 235000013305 food Nutrition 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 22
- 230000029087 digestion Effects 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000004806 packaging method and process Methods 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 11
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 235000020778 linoleic acid Nutrition 0.000 description 11
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 11
- 229960004488 linolenic acid Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 229910001424 calcium ion Inorganic materials 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 229910001425 magnesium ion Inorganic materials 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000037862 Ion Transporter Human genes 0.000 description 4
- 108091006671 Ion Transporter Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000020603 homogenised milk Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000010008 shearing Methods 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 235000020238 sunflower seed Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 235000008476 powdered milk Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091005462 Cation channels Proteins 0.000 description 2
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 102000003563 TRPV Human genes 0.000 description 2
- 108060008564 TRPV Proteins 0.000 description 2
- 235000019498 Walnut oil Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000020191 long-life milk Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000008170 walnut oil Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides formula milk powder capable of improving mineral absorption and a preparation method thereof, in particular to infant formula milk powder which contains a composition of alpha-lactalbumin, beta-casein and vitamin B2, wherein the mass ratio of the alpha-lactalbumin to the beta-casein to the vitamin B2 is (900-7000): (1100-9000): (0.31-2.4), the alpha-lactalbumin accounts for 9-50% of the total protein content, and the beta-casein accounts for 10.5-60% of the total protein content.
Description
Technical Field
The invention belongs to the technical field of infant and child formulas, and particularly relates to infant formula milk powder capable of improving mineral absorption and a preparation method thereof.
Background
Breast milk is the most ideal natural food for infants, and infant formula food mother emulsion plays an important role in digestion and absorption of infant nutrient substances, normal physiological functions, growth and development, immune function construction and the like. Compared with breast milk, infant formulas have great differences in nutrient content, structure and nutrient digestibility.
Mineral elements such as calcium, magnesium and zinc are closely related to bone and tooth development, immune system enhancement, intelligence development and the like in the growth process of infants. The absorption and utilization rate of the breast milk mineral substances is higher than that of infant formulas, so that the recommended strengthening level of the current national standard on most mineral substances in the infant formulas is higher than the general level of the breast milk. Therefore, how to improve the mineral absorption rate is a technical problem to be solved in the prior art.
The absorption of minerals calcium, magnesium and zinc is affected by various factors such as the age and health status of the organism, other nutritional ingredients in the diet, eating habits, medicines and the like. Vitamin B 2 participates in redox reaction in human body in two forms of FAD (flavin adenine dinucleotide) and FMN (flavin mononucleotide), is a constituent component of various important coenzymes in the body, and plays an important role in maintaining normal metabolism of protein, lipid and carbohydrate, promoting normal growth and development, maintaining skin and mucous membrane integrity and the like.
Disclosure of Invention
According to the invention, the effects of promoting the absorption and absorption of mineral calcium, magnesium and zinc are realized by adjusting the contents of protein subfractions alpha-lactalbumin, beta-casein and vitamin B2, and the synchronous increase of the alpha-lactalbumin, the beta-casein and the vitamin B2 in the composition can promote the absorption of the mineral, so that a certain synergistic effect is suggested.
Thus, in a first aspect, the present invention provides a formula for enhancing mineral absorption, said formula comprising a combination of alpha-lactalbumin, beta-casein and vitamin B2, wherein the mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 is (900-7000): (1100-9000): (0.31-2.4), the alpha-lactalbumin accounts for 9-50% of the total protein content, and the beta-casein accounts for 10.5-60% of the total protein content.
The composition of alpha-lactalbumin, beta-casein and vitamin B2 in the invention can promote mineral absorption, increase mineral absorption rate and promote the expression of mineral transporter proteins (OGR 1, TRPV4 and ZnT 1). In the composition, the mass ratio of the alpha-lactalbumin to the beta-casein to the vitamin B2 is (900-7000): (1100-9000): (0.31-2.4), the alpha-lactalbumin accounts for 9-50% of the total protein content, and the beta-casein accounts for 10.5-60% of the total protein content.
As a preferred embodiment, the formula of the present invention comprises the following components in a mass ratio of (900-5500): (1100-7500): (0.31-2.0), the alpha-lactalbumin accounts for 9-45% of the total protein content, and the beta-casein accounts for 10.5-50% of the total protein content.
As a preferred embodiment, the formula of the present invention comprises the following components in a mass ratio of (1000-5500): (1100-7500): (0.4-2.0), the alpha-lactalbumin accounts for 10-45% of the total protein content, and the beta-casein accounts for 10.5-56% of the total protein content.
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (900-5450): (1100-7400): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (1100-5400): (1200-7400): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (1200-5400): (1300-7400): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (1300-5400): (1400-7400): (0.31-2.0).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (1400-5300): (1600-7100): (0.31-2.0).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (1500-5200): (1800-6900): (0.31-2.0).
According to some embodiments of the invention, the formula of the invention comprises the following components in mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (1600-5100): (2000-6700): (0.31-2.0).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (1700-5000): (2100-6500): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (1800-4900): (2300-6300): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (1900-4800): (2400-6200): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (2000-4800): (2500-6100): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises alpha-lactalbumin, beta-casein and vitamin B2 in a mass ratio of (2100-4700): (2600-6000): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.31-2.0).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.33-1.8).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.35-1.6).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.38-1.5).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.4-1.4).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.42-1.3).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.45-1.2).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.5-1.2).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2200-4700): (2700-5900): (0.5-1.15).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2300-4600): (2700-5900): (0.5-1.15).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2300-4600): (2800-5800): (0.5-1.15).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2300-4600): (2800-5800): (0.55-1.15).
According to some embodiments of the invention, the formula according to the invention comprises alpha-lactalbumin, beta-casein and vitamin B2 in a mass ratio of (2400-4500): (2900-5700): (0.55-1.15).
According to some embodiments of the invention, the formula according to the invention comprises the following components in the mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (2600-4300): (2900-5500): (0.6-1.15).
According to some embodiments of the invention, the formula according to the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (2700-4000): (2900-5000): (0.7-1.15).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (2800-3500): (2900-4500): (0.8-1.15).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 of (2900-3200): (2900-4000): (0.85-1.15).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (3000-3100): (3000-3500): (0.9-1.15).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (3000-3100): (3000-3200): (0.95-1.15).
According to some embodiments of the invention, the formula of the invention comprises the following components in a mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 (3000-3100): (3000-3100): (1.0-1.1).
According to some embodiments of the invention, the alpha-lactalbumin comprises 9.2% to 45% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 9.5% to 45% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 10% to 45% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 11% -45% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 13% to 44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 15% to 44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 17% to 44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 18% to 44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 19% -44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 20% to 44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 21% -44% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 22% -43% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 23% -41% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 24% to 39% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 25% to 37% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 26% to 35% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 27% -33% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 28% -31% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the alpha-lactalbumin comprises 28% -30% of the total protein content in the formula of the invention.
According to some embodiments of the invention, the beta-casein is present in the formula of the invention in an amount of 10.5% to 54% of the total protein content.
According to some embodiments of the invention, the beta-casein is present in the formula of the invention in an amount of 10.5% to 52% of the total protein content.
According to some embodiments of the invention, the beta-casein is present in the formula of the invention in an amount of 10.5% to 50% of the total protein content.
According to some embodiments of the invention, the formula according to the invention comprises between 11% and 50% of the total protein content of beta-casein.
According to some embodiments of the invention, the beta-casein is present in the formula of the invention in an amount of 12% -50% of the total protein content.
According to some embodiments of the invention, the beta-casein comprises 13% -50% of the total protein content in the formula.
According to some embodiments of the invention, the beta-casein comprises 14% -50% of the total protein content in the formula.
According to some embodiments of the invention, the beta-casein is present in the formula of the invention in an amount of 16% -48% of the total protein content.
According to some embodiments of the invention, the formula according to the invention comprises between 18% and 46% of the total protein content of beta-casein.
According to some embodiments of the invention, the formula according to the invention comprises 20% -44% of the total protein content of beta-casein.
According to some embodiments of the invention, the beta-casein comprises 21% -42% of the total protein content in the formula.
According to some embodiments of the invention, the beta-casein is present in the formula of the invention in an amount of 22% -40% of the total protein content.
According to some embodiments of the invention, the beta-casein comprises 23% -38% of the total protein content in the formula.
According to some embodiments of the invention, the beta-casein comprises 24% -36% of the total protein content in the formula.
According to some embodiments of the invention, the formula according to the invention comprises between 25% and 34% of the total protein content of beta-casein.
According to some embodiments of the invention, the beta-casein comprises 26% -32% of the total protein content in the formula.
According to some embodiments of the invention, the beta-casein comprises 27% -31% of the total protein content in the formula.
According to some embodiments of the invention, the formula according to the invention comprises between 28% and 30% of the total protein content of beta-casein.
In the present invention, the alpha-lactalbumin is derived from skim milk powder, concentrated whey protein powder, whey protein powder of different alpha-lactalbumin content or other raw materials which can provide alpha-lactalbumin.
In the present invention, the beta-casein is derived from skim milk powder, casein powder of different beta-casein content or other raw materials providing beta-casein.
In the present invention, the source of vitamin B2 comprises one or more of riboflavin, riboflavin-5' -sodium phosphate.
In the formula milk powder, each 100g of the formula milk powder comprises 9-23g of protein, 15-30g of fat, 0.85-7.5g of dietary fiber and 50-59g of carbohydrate.
In the invention, the sources of the proteins comprise any one or more of raw cow milk, whey protein powder, desalted whey powder, alpha-whey protein powder, beta-casein powder and skim milk powder, wherein the mass content of the whey proteins in the proteins is 36-70%. In one embodiment of the present invention, the raw materials include, based on 1000 parts by weight of the formula: raw milk 0-3600 weight parts and skimmed milk powder 0-500 weight parts, wherein part or all of raw milk and skimmed milk powder can be replaced by whole milk powder and skimmed milk with equivalent protein amount. In one embodiment of the present invention, the raw materials include, based on 1000 parts by weight of the formula: 0-200 parts of whey protein powder, 0-450 parts of desalted whey powder, 0-55 parts of alpha-whey protein powder and 0-45 parts of beta-casein powder.
In the present invention, the source of fat includes any one or more of milk fat and vegetable oil. The vegetable oil comprises one or more of sunflower seed oil, corn oil, soybean oil, canola oil, coconut oil, palm oil, perilla oil or walnut oil. The addition of these vegetable oils provides the formula with a fatty component on the one hand and linoleic acid on the other hand, and at the same time alpha-linolenic acid and DHA. In the invention, the content of linoleic acid in the sunflower seed oil is 7.6-8.9%, and the content of alpha-linolenic acid is 0.25-0.38%; the content of linoleic acid in the corn oil is 53.0-56.20%, and the content of alpha-linolenic acid is 0.9-1.6%; the content of linoleic acid in the soybean oil is 48.0-53.5%, and the content of alpha-linolenic acid is 7.6-11.2%; the content of linoleic acid in the canola oil is 16-19%, and the content of alpha-linolenic acid is 8.0-10.6%; the content of linoleic acid in the coconut oil is 1-3%, and the content of alpha-linolenic acid is 0-1%; the content of linoleic acid in the palm oil is 5.2-16.6%, and the content of alpha-linolenic acid is 0-0.32%; the content of linoleic acid in the perilla oil is 13.0-17.0%, and the content of alpha-linolenic acid is 55.0-61.0%; the content of linoleic acid in the walnut oil is 53.2-61.9%, and the content of alpha-linolenic acid is 6.7-16.9%; the content of linoleic acid in the milk fat is 2.0-2.6%, the content of alpha-linolenic acid is 0.2-0.95%, and the content of DHA is 0.01-0.023%. In addition, the raw material for providing fat can also optionally comprise raw material OPO structural fat added for providing 1, 3-dioleoyl-2-palmitic acid triglyceride, wherein the content of the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride is 40% -70%. The OPO structural grease comprises 5.9-6.3% of linoleic acid and 0.4-0.62% of alpha-linolenic acid, and the effective content of 1, 3-dioleoyl-2-palmitic acid triglyceride in the raw material of the OPO structural grease is 40% -70%. In one embodiment of the present invention, the raw materials include, based on 1000 parts by weight of the formula: 0-80 parts by weight of sunflower seed oil; corn oil 0-50 weight portions; 0-80 parts by weight of soybean oil; OPO structural fat 0-140 weight portions.
In the present invention, the source of dietary fiber includes one or more of fructooligosaccharides, galactooligosaccharides, raffinose, breast milk oligosaccharides.
In the formula of the present invention, the carbohydrate is partly derived from lactose-containing base stock such as milk, whole milk powder and/or skimmed milk powder etc., and the remainder is derived from additional lactose-containing stock. That is, in the formula of the present invention, the carbohydrate-providing raw material includes lactose as a raw material in addition to lactose-containing base raw material. In one embodiment of the present invention, the raw materials of the formula of the present invention based on 1000 parts by weight comprise: lactose 100-550 weight portions. The specific addition amount of lactose may be adjusted within the range so that the carbohydrate content of the formula of the present invention is 50-59g/100g.
According to a specific embodiment of the invention, the raw materials of the formula milk powder further comprise one or more than two of DHA, ARA, nucleotide and lactoferrin. As a preferred embodiment, the raw materials include, based on 1000 parts by weight of the formula milk powder: 0-15 parts of DHA, 0-25 parts of ARA, 0-1.5 parts of lactoferrin and 0-0.8 part of nucleotide.
According to a specific embodiment of the invention, the raw materials of the formula milk powder further comprise compound nutrients comprising calcium powder, vitamins and minerals. The compound nutrient is a combination of nutrient components meeting the national standard, and different addition amounts are used according to different formulas.
As a preferred embodiment, the raw materials include, based on 1000 parts by weight of the formula milk powder: 7-22 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals; more preferably, the compound nutrients are added at least in the form of compound vitamin packs, calcium powder, mineral nutrient packs.
Specifically, the compound nutrient is added in the form of the following nutrition packages:
1) The compound vitamin nutrition package comprises the following components in each gram of compound vitamin nutrition package: taurine: 130-220mg of the total weight of the composition,
Vitamin a:1400-2700 mu gRE,
Vitamin D: 30-68. Mu.g of the total,
Vitamin B 1: 1400-3200. Mu.g of the total weight of the composition,
Vitamin B 2: 880-4000. Mu.g of the total amount of the components,
Vitamin B 6: 1040-2800 mug of the total weight of the composition,
Vitamin B 12: 4-10 mu g of the total weight of the medicine,
Vitamin K 1: 150-320. Mu.g of the total,
Vitamin C:145-500 the dosage of the medicine is more than one mg,
Vitamin E:12-50mg of alpha-TE, and,
Nicotinic acid: 10000-23000 mug of the total weight of the composition,
Folic acid: 210-420 mug of the total weight of the product,
Biotin: 30-85 mu g of the total weight of the medicine,
Pantothenic acid: 7100-13800 mug of the powder,
Inositol: 0-250mg of the total amount of the components,
L-carnitine: 0-60mg of the total weight of the composition,
2) The mineral substance-nutrition package comprises the following components in each gram of the mineral substance-nutrition package: iron: 45-95mg of the total weight of the composition,
Zinc: 22-78 the dosage of the medicine is more than one mg,
Copper: 2600-4420. Mu.g,
Iodine: 500-1550 mug of the total weight of the product,
Selenium: 0-260. Mu.g of the total weight of the composition,
Manganese: 0-810 mu g of the total weight of the mixture,
3) The mineral substance two-nutrition package comprises the following components in each gram of the mineral substance two-nutrition package: calcium: 150-345mg of the total weight of the composition,
Phosphorus: 35-150mg, sodium: 5-96mg of the extract, wherein the extract is prepared from 5-96mg of the extract,
4) The effective content of magnesium in the magnesium chloride nutrition bag is 10% -16%,
5) The effective content of potassium in the potassium chloride nutrition package is 49% -53%,
6) The choline chloride nutrition packet has an effective content of 72% -76% of choline.
As a preferred embodiment, based on 1000 parts by weight of the formula milk powder, the addition amount of the compound vitamin nutrition package is 2-4 parts by weight, the addition amount of the mineral two nutrition package is 2-25 parts by weight, the addition amount of the mineral one nutrition package is 0.5-3 parts by weight, the addition amount of the magnesium chloride nutrition package is 0-3.5 parts by weight, the addition amount of the potassium chloride nutrition package is 0-4.5 parts by weight, the addition amount of the choline chloride nutrition is 0-2.5 parts by weight, and the base material of each nutrition package is preferably lactose or L-sodium ascorbate;
According to a specific embodiment of the invention, the raw materials of the formula according to the invention also comprise probiotics.
As a preferred embodiment, the probiotic is bifidobacteria.
As a preferred embodiment, the bifidobacterium is added in an amount of 0.1 to 0.4 parts by weight, more preferably 0.15 to 0.2 parts by weight,
As a preferred embodiment, the content of bifidobacteria per part by weight of the bifidobacteria powder is 3X 10 10 CFU or more.
According to a specific embodiment of the present invention, the formula raw materials of the present invention comprise:
In the formula milk powder, the specific dosage of each raw material is determined by adjusting on the premise of meeting the index requirement of the formula milk powder product. In the formula milk powder, the performance indexes of the products which are not specified or listed in detail are implemented according to the national standard of the formula milk powder or the national standard of the prepared milk powder and the regulations of related standards and regulations.
In the formula milk powder, all raw materials are commercially available, and the raw materials are selected to meet the related standard requirements, wherein the protein composition meets the requirements of the invention. In addition, the compound nutrient can also be self-compounded. The invention adopts 'compound' for convenience of expression, and does not mean that all components in the compound are mixed together and then applied. All raw materials should be added and used on the premise of meeting related regulations.
According to a specific embodiment of the invention, the formula of the invention is a formula suitable for infants and children of 0-7 years old, and the formula has better protein digestion and absorption.
In a second aspect, the present invention provides a method of preparing the formula of the first aspect of the invention, comprising: proportioning, homogenizing, concentrating, sterilizing, spray drying and dry mixing to obtain the finished product.
As a preferred embodiment, the method comprises:
Mixing the milk, powder raw materials and melted grease raw materials subjected to rough filtration and homogenization sterilization, adding galactooligosaccharide syrup into a small hopper, and adding a compound nutrition enhancer, a magnesium chloride nutrition package, a potassium chloride nutrition package and a choline chloride nutrition package into a nutrition jar to obtain mixed feed liquid; filtering, homogenizing, cooling, concentrating, sterilizing, spray drying, fluidized bed drying, cooling to obtain dry milk powder, mixing with DHA, ARA, lactoferrin, nucleotide and Bacillus bifidus, and sieving to obtain the formula milk powder.
As a preferred embodiment, the primary pressure of the homogenization treatment of the mixed liquor is 105+ -5 bar, and the secondary pressure is 32+ -3 bar.
As a preferred embodiment, the concentration sterilization adopts double-effect concentration, more preferably, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; further preferably, the discharge concentrations are all 48% -52% dry matter.
As a preferred embodiment, the spray drying has an inlet air temperature of 165-180℃and an outlet air temperature of 75-90℃and a high pressure pump pressure of 160-210bar and a column vacuum of-4 mbar to-2 mbar.
As a preferred embodiment, the fluidized bed drying and cooling comprises two drying and cooling steps, and the temperature of the milk powder after the two drying and cooling steps is 25-30 ℃; and mixing phospholipid with carrier, heating to 60-65deg.C, and dispersing on the surface of milk powder under the action of compressed air.
In one embodiment of the present invention, the preparation process of the formula of the present invention comprises the following specific steps:
1) Coarse filtration of milk: after coarse filtration and degassing of the balance cylinder, the milk is preheated by a plate heat exchanger and then separated from impurities by a separator.
2) Homogenizing and sterilizing milk: part of the milk after removing the impurities enters a homogenizer for homogenization, the other part of the milk is not homogenized, the homogenized milk and the non-homogenized milk are mixed and then enter a sterilizing system for sterilization, and the sterilized milk enters a mixing tank.
3) Powder adding: premixing lactose and casein powder raw materials according to an optimal ratio of 5:1, keeping the temperature of ingredients at 35-55 ℃, and adopting a high shearing technology, wherein the shearing rotating speed is higher than 1590r/min. The other various powder raw materials are uniformly added into a powder preparation tank for storage through an air-assisted system after being metered according to the formula.
4) Vacuum powder suction: various powder raw materials in the powder preparation tank are sucked into the mixing tank through a vacuum system.
5) Melting and oil preparing: the oil and fat specified in the formula are placed into an oil melting room according to the formula requirement, the temperature of the oil melting room is kept at 50-90 ℃, and after the oil is melted, the oil is pumped into a mixed oil storage tank according to the formula proportion requirement through an oil pump and a flowmeter.
6) And (3) storing the mixed oil: the mixed oil is stored in an oil storage tank in a heat-preserving way at 40-50 ℃ for less than 12 hours to prevent fat oxidation.
7) Weighing: and pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement.
8) And (3) dissolving and adding a compound nutrition enhancer: the compound nutrient supplement I, the compound nutrient supplement II, the compound nutrient supplement III, the compound magnesium chloride nutrient package, the compound potassium chloride nutrient package and the choline chloride are respectively added, and after being respectively dissolved by 100-200kg purified water, the mixture is put into a mixing tank, and the adding tank and the pipeline are flushed by 100kg purified water every time.
9) And (3) adding small materials: and adding a galactooligosaccharide paddle into the small hopper, and extracting into a mixing tank.
10 Filtering: and mixing all the raw materials in a mixing tank, and filtering the mixed feed liquid by a filter screen to remove physical impurities possibly carried in the raw materials.
11 Homogenizing: homogenizing the mixed feed liquid by a homogenizer, wherein the primary pressure is 105+/-5 bar, the secondary pressure is 32+/-3 bar, and mechanically treating the fat globules to disperse the fat globules into uniform fat globules.
12 Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling, the temperature is lower than 20 ℃, the homogenized feed liquid is temporarily stored in a pre-storing cylinder, the next working procedure is carried out within 6 hours, and a stirrer is started according to set requirements.
13 Concentration sterilization: during production, double-effect concentration is used, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; the discharge concentration is 48% -52% of dry matter.
14 Concentrated milk storage, pre-heating filtration, spray drying: temporarily storing the concentrated milk in a concentrated milk balance tank; preheating to 60-70deg.C by scraper preheater, filtering the preheated material by 1mm pore diameter filter, spraying with high pressure pump, drying, and agglomerating fine powder on top of tower or fluidized bed; wherein the air inlet temperature is 165-180 ℃, the air outlet temperature is 75-90 ℃, the high-pressure pump pressure is 160-210bar, and the negative pressure of the tower is-4 mbar to-2 mbar.
15 Fluidized bed drying and cooling: the milk powder from the drying tower is subjected to secondary drying by a fluidized bed (first stage) and then is cooled to 25-30 ℃ by the fluidized bed (second stage); and meanwhile, the phospholipid and the carrier are mixed and then heated to 60-65 ℃, and the phospholipid is uniformly dispersed on the surface of the milk powder under the action of compressed air, so that the granularity and the quick solubility of the powder particles are increased by agglomerating the powder particles.
16 Split charging: and weighing DHA, ARA, lactoferrin, nucleotide and bifidobacterium according to the formula requirement, sealing bags and subpackaging.
17 Dry blending): and uniformly mixing the weighed DHA, ARA, lactoferrin, nucleotide, bifidobacterium and milk powder in a dry mixer.
18 Screening powder: the granularity of the milk powder is uniform through the vibrating screen, and the powder slag is scrapped.
19 Powder discharge: and (3) receiving powder by using a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room.
20 Powder) is added: and pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.
21 Packaging: nitrogen filling and packaging of automatic packaging machines with different specifications; the oxygen content is lower than 1-5% when nitrogen is filled.
22 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine.
23 Inspection of the finished product: sampling and checking the packaged product according to a checking plan.
24 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
In a third aspect, the present invention provides the use of a formula according to the first aspect of the invention for the preparation of a product for enhancing mineral absorption.
According to a specific embodiment of the present invention, the enhancing mineral absorption comprises increasing mineral absorption and increasing mineral transporter expression. As a preferred embodiment, the mineral transporter comprises TRPV4, OGR1 and/or ZnT1.
In some embodiments of the invention, the product is a food product.
In some embodiments of the invention, the food product comprises a pediatric food product, an infant formula, a follow on infant formula, a toddler formula, or a special medical use infant formula
According to some embodiments of the invention, the food product according to the invention has an alpha-lactalbumin content of 900-7000mg/100g, a beta-casein content of 1100-9000mg/100g and a vitamin B2 content of 0.31-2.4mg/100g, based on dry matter of the food product. And the content of each substance meets the requirements of related standards.
According to some embodiments of the invention, the alpha-lactalbumin is present in an amount of 900-5500mg/100g, the beta-casein is present in an amount of 1100-7500mg/100g, and the vitamin B2 is present in an amount of 0.31-2.0mg/100g.
According to some embodiments of the invention, the alpha-lactalbumin is present in an amount of 930-5000mg/100g, the beta-casein is present in an amount of 1100-7000mg/100g, and the vitamin B2 is present in an amount of 0.31-2.0mg/100g.
According to some embodiments of the invention, the alpha-lactalbumin is present in an amount of 1000-6500mg/100g, the beta-casein is present in an amount of 1200-9000mg/100g, and the vitamin B2 is present in an amount of 0.31-2.2mg/100g.
According to some embodiments of the invention, the content of alpha-lactalbumin is 1100-5400mg/100g, the content of beta-casein is 1200-7400mg/100g, and the content of vitamin B2 is 0.31-2.0mg/100g.
According to some embodiments of the invention, the alpha-lactalbumin is present in an amount of 1200-5400mg/100g, the beta-casein is present in an amount of 1200-7400mg/100g, and the vitamin B2 is present in an amount of 0.31-2.0mg/100g.
According to some embodiments of the invention, the food product according to the invention has an alpha-lactalbumin content of 1400-5300mg/100g, a beta-casein content of 1600-7100mg/100g and a vitamin B2 content of 0.31-2.0mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises an alpha-lactalbumin content of 1500-5200mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises an alpha-lactalbumin content of 1600-5100mg/100g.
According to some embodiments of the invention, the food product according to the invention has an alpha-lactalbumin content of 1700-5000mg/100g.
According to some embodiments of the invention, the food product according to the invention has an alpha-lactalbumin content of 1800-4900mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises a content of alpha-lactalbumin of 1900-4800mg/100g.
According to some embodiments of the invention, the food product according to the invention has an alpha-lactalbumin content of 2000-4700mg/100g.
According to some embodiments of the invention, the food product according to the invention has an alpha-lactalbumin content of 2100-4700mg/100g.
According to some embodiments of the present invention, the food product according to the present invention has an alpha-lactalbumin content of 2200-4600mg/100g, more preferably 2300-4300mg/100g, more preferably 2400-4100mg/100g, more preferably 2500-3900mg/100g, more preferably 2600-3700mg/100g, more preferably 2700-3500mg/100g, more preferably 2800-3300mg/100g, more preferably 2900-3200mg/100g, more preferably 3000-3100mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises beta-casein in an amount of 1800-6900mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises beta-casein in an amount of 2000-6700mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises beta-casein in an amount of 2200-6500mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises beta-casein in an amount of 2400-6300mg/100g.
According to some embodiments of the invention, the food product according to the invention comprises beta-casein in an amount of 2600-6100mg/100g.
According to some embodiments of the invention, the food product according to the invention has a beta-casein content of 2700-5900mg/100g, more preferably 2800-5800mg/100g, more preferably 2800-5500mg/100g, more preferably 2800-5000mg/100g, more preferably 2800-4500mg/100g, more preferably 2850-4000mg/100g, more preferably 2900-3500mg/100g, more preferably 2900-3300mg/100g, more preferably 2950-3200mg/100g, more preferably 3000-3100mg/100g.
According to some embodiments of the invention, the content of vitamin B2 in the food product according to the invention is 0.35-1.9mg/100g.
According to some embodiments of the invention, the vitamin B2 content in the food product according to the invention is 0.4-1.8mg/100g.
According to some embodiments of the invention, the vitamin B2 content of the food product according to the invention is 0.45-1.7mg/100g.
According to some embodiments of the invention, the vitamin B2 content in the food product according to the invention is 0.5-1.6mg/100g.
According to some embodiments of the invention, the vitamin B2 content of the food product according to the invention is 0.55-1.5mg/100g.
According to some embodiments of the invention, the vitamin B2 content in the food product according to the invention is 0.6-1.4mg/100g.
According to some embodiments of the present invention, the content of vitamin B2 in the food product according to the present invention is 0.7-1.3mg/100g, more preferably 0.8-1.25mg/100g, more preferably 0.9-1.2mg/100g, more preferably 0.95-1.15mg/100g, more preferably 1.0-1.1mg/100g.
According to a specific embodiment of the invention, the product is a formula milk powder. As a preferred embodiment, the product is an infant formula, a baby formula or a child formula.
In the present invention, the total protein in the composition or the formula is the sum of all proteins in the composition or the formula. When the composition or formula of the present invention further comprises other proteins than alpha-lactalbumin, beta-casein, unless otherwise specified, the total protein is the sum of alpha-lactalbumin, beta-casein and the other proteins. When the protein in the composition or formula of the invention only comprises alpha-lactalbumin and beta-casein, the total protein is the sum of the alpha-lactalbumin and the beta-casein.
The beneficial effects are that:
The invention provides a formula milk powder capable of improving mineral absorption, which can improve the mineral absorption effect, and has the specific technical effects of increasing the absorption rate of mineral calcium, magnesium and zinc and promoting the expression of mineral transport proteins (OGR 1, TRPV4 and ZnT 1).
Drawings
FIG. 1 is a graph showing the calcium absorption rate statistics in an embodiment of the present invention;
FIG. 2 is a graph showing statistics of magnesium absorption in an embodiment of the present invention;
FIG. 3 is a graph showing statistics of zinc absorption rate in an embodiment of the present invention;
FIG. 4 is a statistical chart of the expression amount of the transporter TRPV4 in the embodiment of the present invention;
FIG. 5 is a graph showing statistics of expression amounts of the transporter OGR1 in the embodiment of the present invention;
FIG. 6 is a statistical graph of the expression level of the transferrin ZnT1 according to the embodiment of the invention.
Detailed Description
Before the embodiments of the invention are further described, it is to be understood that the invention is not limited in its scope to the specific embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, materials used in the embodiments, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present invention may be used to practice the present invention according to the knowledge of one skilled in the art and the description of the present invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all employ techniques conventional in the art.
The technical solutions of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The invention applies a composition to infant milk powder, the composition is composed of alpha-lactalbumin, beta-casein and vitamin B 2, and the mass ratio of the alpha-lactalbumin, the beta-casein and the vitamin B 2 is (1200-7000): (1200-9000): (0.31-2.4), the alpha-lactalbumin accounts for 10.5-50% of the total protein content, and the beta-casein accounts for 10.5-60% of the total protein content.
As a preferred embodiment, the mass ratio of α -lactalbumin, β -casein and vitamin B 2 is (1200-5500): (1200-7500): (0.31-2.0), the alpha-lactalbumin accounts for 10.5-45% of the total protein content, and the beta-casein accounts for 10.5-50% of the total protein content.
The technical effects are to improve the absorption rate of minerals (calcium, magnesium and zinc) and promote the expression of mineral transport proteins (OGR 1, TRPV4 and ZnT 1).
The invention also provides application of the composition in products for improving the expression quantity of mineral transport proteins.
The invention provides 5 experimental examples, and the influence of nutritional compositions with different contents of alpha-lactalbumin, beta-casein and vitamin B 2 on the indexes related to mineral (calcium, magnesium and zinc) absorption is evaluated by adopting an in-vitro gastrointestinal digestion model and a Caco-2 cell in-vitro absorption model.
Compared with experimental example 1, experimental example 2 adjusts the protein subfractions by strengthening alpha-lactalbumin and beta-casein, and the result shows that the absorption of mineral calcium, magnesium and zinc can be improved by adjusting the protein subfractions, the expression amounts of TRPV4, OGR1 and ZnT1 are increased, but the absorption rate of magnesium, the expression amounts of OGR1 and ZnT1 only have an increasing trend, and the difference is not significant.
Compared with experimental example 2, experimental example 3 increases the vitamin B 2 content in an in vitro digestion and absorption system, and the result shows that the absorption rate of mineral calcium and zinc in experimental example 3 is obviously increased, the absorption rate of magnesium is in a trend of increasing, but compared with experimental example 1, the difference is obvious; the expression amounts of the mineral transporter TRPV4, OGR1 and ZnT1 all have the tendency to increase, but the difference is not significant; it is suggested that vitamin B 2 may have an improving effect on the absorption rate of minerals calcium, magnesium and zinc.
Compared with experimental example 3, experimental example 4 further strengthens the contents of alpha-lactalbumin, beta-casein and vitamin B 2 on the basis of experimental example 3, and the result shows that the absorption rate of mineral calcium, magnesium and zinc is further improved; the expression levels of the mineral transporter TRPV4, OGR1 and ZnT1 are all obviously increased. Experimental example 5 further adjusts the contents of alpha-lactalbumin and beta-casein, and the results show that compared with experimental example 4, the absorption rate of calcium, magnesium and zinc and the mineral transporter are reduced, wherein the absorption rate of calcium and magnesium is obviously reduced, and the expression level of the transporter OGR1 and ZnT1 of magnesium and zinc is also obviously reduced.
Example 1
The specific technical scheme of the in vitro gastrointestinal digestion and Caco-2 cell in vitro absorption experiment is as follows:
Test sample and test method
1. Preparation of mineral milk protein and vitamin B 2 -containing composition
According to the protein content of the sample, the total protein concentration is adjusted to 10mg/mL by deionized water, 50mL of milk protein sample is prepared, and the addition amount of mineral is referenced to the addition level of mineral in infant formula, namely 0.119g of mineral mixture is correspondingly added per g of protein. And adding riboflavin according to vitamin B 2 content to prepare nutritional composition containing mineral protein and vitamin B 2.
The nutritional composition content in each experimental example is shown in table 1 below:
table 1 content of nutritional compositions in each experimental example
2. In vitro gastrointestinal digestion experiments
Simulating the preparation of gastric juice and the gastric digestion experimental process: 4.35mg pepsin and 23.755mg gastric lipase are weighed, 45mL of NaCl solution with the concentration of 0.15M is added, the pH is adjusted to 4.0 by using 1M hydrochloric acid, the volume is fixed to 50mL to form simulated gastric juice, the pepsin concentration in the system is 113.75U/mL, and the final gastric lipase concentration is 21U/mL.
The simulated gastric fluid was preheated in a 37 ℃ water bath for 20min. 25mL of the milk was added to 25mL of gastric digest in an enzyme reactor (37 ℃), samples were taken at 0min of digestion, 5mL were taken, and the reaction was stopped by adjusting the pH to 7.0 with 1M NaOH.
Simulating intestinal digestion solution preparation and intestinal digestion solution experiment processes, namely dissolving trypsin and bile salt into a mixed solution consisting of 50mmol/LKH 2PO 4, 20mM CaCl 2 and 0.15mol/L NaCl, respectively adjusting the pH of the solution to 6.5, wherein the concentration of system enzyme is 17.26U/mL and 2.64 mg/mL.
The pH of the sample after the gastric digestion is adjusted to 6.5, simulated intestinal digestion solution is added in an equal volume, the sample is heated at 95 ℃ for 5min during the digestion for 120min to inactivate enzymes, and the reaction is stopped.
3. Caco-2 cell in vitro absorption experiment
Modeling in vitro absorption by Caco-2 cells: 0.3mL of cell suspension (105/mL) is added into the upper chamber of the Transwell plate, 1.3-1.5mL of fresh culture medium containing 20% FBS is added into the lower chamber, after the cells are attached, the liquid is changed once a day, the resistance value is measured when the liquid is changed, and when the cells are cultured for 21 days, the resistance value is measured, and the resistance value reaches 400 Ω cm < 2> or more, thus the modeling is successful.
Cell transport: the old culture medium is poured out, changed into Hanks equilibrium solution, and incubated in an incubator for 30min. The upper and lower chambers were each washed 3 times with Hanks equilibration solution, the lower chamber was filled with 1.5mLHanks equilibration solution, the upper chamber was filled with 0.3mL sample solution, and the time was 2 hours, and the lower solution was aspirated for subsequent index determination.
4. Mineral absorption related index determination
(1) Determination of mineral content: the mineral substances are measured by adopting the 'multi-element measurement in national food safety Standard of GB 5009.268-2016'.
Mineral absorption was calculated according to the following formula.
(2) Determination of mineral transporter expression levels
Caco-2 cell lysis: after 3 washes with PBS, 0.6mL of medium and 0.6mL of sample were added, the liquid was decanted after 24h of intervention, washed 3 times with PBS, 200. Mu.L of cell lysate (containing 1 mMPMSF) was added, and after 1-2s of treatment, the liquid was aspirated into a centrifuge tube. The whole process is carried out on ice, the temperature is 4 ℃,5000g is centrifugated for 5min, and the supernatant is taken.
Protein concentration in the supernatant was measured by BCA method, and the transport protein content in the supernatant was measured by experimental procedures according to the ELISA kit protocol.
Experimental results
(1) Mineral absorption rate
It has been found that peptides produced after digestion of alpha-lactalbumin, beta-casein have a high content of negative charges, such as casein phosphopeptides, which are effective in binding divalent cations to form soluble complexes that promote mineral absorption. In addition, the spatial structure of the intestinal epithelial cells is changed after the minerals are combined, and some intestinal epithelial cells resist digestion of further gastrointestinal tract enzymes, so that the intestinal epithelial cells can be smoothly reached and absorbed. After the samples of each experimental example are digested by an in-vitro gastrointestinal digestion model, an equal amount of digestive juice is taken to pass through a Caco-2 cell in-vitro absorption model, the contents of the digestive juice and mineral substances (calcium, magnesium and zinc) transported to a lower chamber are respectively measured, and the mineral substance absorption rate is calculated.
As shown in fig. 1-3, the results show that compared with experimental example 1, the absorption rate of calcium and zinc of experimental example 2 is obviously increased, the absorption rate of magnesium has an increasing trend, but no obvious difference, and the absorption rate of mineral calcium, magnesium and zinc can be improved through the composition of the sign protein subfractions; on the basis of experiment example 2, the vitamin B 2 content is increased in an in-vitro digestion and absorption system, and the result shows that the absorption rate of mineral calcium and zinc in experiment example 3 is obviously increased, and the absorption rate of magnesium is obviously increased, but compared with experiment example 1, the difference is obvious, so that the vitamin B 2 possibly has an improvement effect on the absorption rate of the mineral calcium, magnesium and zinc. Experimental example 4 further strengthens the contents of alpha-lactalbumin, beta-casein and vitamin B 2 on the basis of experimental example 3, and the result shows that the absorption rate of mineral calcium, magnesium and zinc is further improved. Experimental example 5 further adjusts the contents of α -lactalbumin and β -casein, and the results show that the absorption rate of calcium, magnesium, and zinc is reduced compared with experimental example 4, wherein the absorption rates of calcium and magnesium are significantly reduced.
(2) Mineral transporter expression level
The permeation sensitive transient receptor potential channel (TRPV 4) is a non-selective cation channel which is widely distributed in organisms and can permeate calcium ions and magnesium ions, the activity of the non-selective cation channel is regulated by calcium ions, the calcium ions are combined with calcium ion binding protein-calmodulin (CaM) to improve the activity of the TRPV4 so as to promote the inflow of calcium ions and magnesium ions, and the excessive concentration of Ca 2+ can inhibit the activity of the TRPV 4. Analysis of the expression of TRPV4 in different groups revealed that the expression levels of TRPV4 in each of examples 2 to 5 were significantly increased as compared with example 1, and that the expression level of TRPV4 in example 5 was decreased as compared with example 4 (as shown in fig. 4).
OGR1 (SLC 41 A1) is a magnesium ion transporter, a member A1 of the solute carrier family 41, a magnesium ion transporter that is now well studied, plays an important role in transmembrane Mg 2+ transport and, by extrapolation, plays an important role in cellular Mg 2+ homeostasis. The results of analysis of the expression of the magnesium ion transporter OGR1 in the different groups showed that the expression levels of OGR1 in examples 2 to 5 were increased compared to example 1, but the expression levels of OGR1 in examples 2 and 3 tended to be increased, but the difference was not significant, the expression levels of OGR1 in examples 4 and 5 were significantly increased, but the expression level of OGR1 in example 5 was significantly decreased compared to example 4 (as shown in fig. 5).
ZnT1 is a specific transport protein for transporting intracellular zinc into the body, and is an important regulator of the cell zinc steady state. Analysis of the expression of zinc ion transporter ZnT1 in different groups shows that compared with experimental example 1, the expression amount of ZnT1 in experimental examples 2-5 is increased, but experimental examples 2 and 3 only have an increasing trend, but the difference is not significant; the expression levels of ZnT1 in experimental examples 4 and 5 were significantly increased, but the expression level of ZnT1 in experimental example 5 was significantly decreased as compared with experimental example 4. The expression of the above mineral transporter is consistent with the trend of mineral absorption rate (as shown in fig. 6).
In summary, as the enhancement of alpha-lactalbumin, beta-casein and/or vitamin B 2 increases, the absorption rate of mineral calcium, magnesium and zinc and the expression level of corresponding transport protein also increase, but after the enhancement of alpha-lactalbumin and beta-casein reaches a certain content, the absorption rate of mineral calcium, magnesium and zinc and the expression level of corresponding transport protein decrease, which indicates that the expression level of transport protein (OGR 1, TRPV4 and ZnT 1) can be increased within a certain content range of the nutritional composition of alpha-lactalbumin, beta-casein and vitamin B 2, the transport absorption of the cells to minerals (calcium, magnesium and zinc) is improved, and the absorption rate of the mineral calcium, zinc and magnesium is improved.
Example two infant formula with improved mineral absorption
1250 Kg milk, 225 kg lactose, 300 kg desalted whey powder, 60 kg sunflower seed oil, 30 kg corn oil, 20 kg soybean oil, 100 kg OPO structural fat, 20 kg alpha-lactalbumin powder, 10 kg casein powder, 20 kg fructo-oligosaccharide powder, 45 kg galacto-oligosaccharide syrup, 2 kg soybean lecithin, 21 kg compound nutrient package (wherein the compound vitamin nutrient package weighs 3.5 kg, comprises vitamin B 2:2800-3500 micrograms/gram), 12 kg DHA, 14 kg ARA, 0.6 kg nucleotide and 0.3 kg bifidobacterium.
The preparation process is as follows:
1) Coarse filtration of milk: after coarse filtration and degassing of the balance cylinder, the milk is preheated by a plate heat exchanger and then separated from impurities by a separator.
2) Homogenizing and sterilizing milk: part of the milk after removing the impurities enters a homogenizer for homogenization, the other part of the milk is not homogenized, the homogenized milk and the non-homogenized milk are mixed and then enter a sterilizing system for sterilization, and the sterilized milk enters a mixing tank.
3) Powder adding: premixing lactose and casein powder raw materials according to an optimal ratio of 5:1, keeping the temperature of ingredients at 35-55 ℃, and adopting a high shearing technology, wherein the shearing rotating speed is higher than 1590r/min. The other various powder raw materials are uniformly added into a powder preparation tank for storage through an air-assisted system after being metered according to the formula.
4) Vacuum powder suction: various powder raw materials in the powder preparation tank are sucked into the mixing tank through a vacuum system.
5) Melting and oil preparing: the oil and fat specified in the formula are placed into an oil melting room according to the formula requirement, the temperature of the oil melting room is kept at 50-90 ℃, and after the oil is melted, the oil is pumped into a mixed oil storage tank according to the formula proportion requirement through an oil pump and a flowmeter.
6) And (3) storing the mixed oil: the mixed oil is stored in an oil storage tank in a heat-preserving way at 40-50 ℃ for less than 12 hours to prevent fat oxidation.
7) Weighing: and pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement.
8) And (3) dissolving and adding a compound nutrition enhancer: the compound nutrient supplement I, the compound nutrient supplement II, the compound nutrient supplement III, the compound magnesium chloride nutrient package, the compound potassium chloride nutrient package and the choline chloride are respectively added, and after being respectively dissolved by 100-200kg purified water, the mixture is put into a mixing tank, and the adding tank and the pipeline are flushed by 100kg purified water every time.
9) And (3) adding small materials: and adding a galactooligosaccharide paddle into the small hopper, and extracting into a mixing tank.
10 Filtering: and mixing all the raw materials in a mixing tank, and filtering the mixed feed liquid by a filter screen to remove physical impurities possibly carried in the raw materials.
11 Homogenizing: homogenizing the mixed feed liquid by a homogenizer, wherein the primary pressure is 105+/-5 bar, the secondary pressure is 32+/-3 bar, and mechanically treating the fat globules to disperse the fat globules into uniform fat globules.
12 Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling, the temperature is lower than 20 ℃, the homogenized feed liquid is temporarily stored in a pre-storing cylinder, the next working procedure is carried out within 6 hours, and a stirrer is started according to set requirements.
13 Concentration sterilization: during production, double-effect concentration is used, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; the discharge concentration is 48% -52% of dry matter.
14 Concentrated milk storage, pre-heating filtration, spray drying: temporarily storing the concentrated milk in a concentrated milk balance tank; preheating to 60-70deg.C by scraper preheater, filtering the preheated material by 1mm pore diameter filter, spraying with high pressure pump, drying, and agglomerating fine powder on top of tower or fluidized bed; wherein the air inlet temperature is 165-180 ℃, the air outlet temperature is 75-90 ℃, the high-pressure pump pressure is 160-210bar, and the negative pressure of the tower is-4 mbar to-2 mbar.
15 Fluidized bed drying and cooling: the milk powder from the drying tower is subjected to secondary drying by a fluidized bed (first stage) and then is cooled to 25-30 ℃ by the fluidized bed (second stage); and meanwhile, the phospholipid and the carrier are mixed and then heated to 60-65 ℃, and the phospholipid is uniformly dispersed on the surface of the milk powder under the action of compressed air, so that the granularity and the quick solubility of the powder particles are increased by agglomerating the powder particles.
16 Split charging: and weighing DHA, ARA, lactoferrin, nucleotide and bifidobacterium according to the formula requirement, sealing bags and subpackaging.
17 Dry blending): and uniformly mixing the weighed DHA, ARA, lactoferrin, nucleotide, bifidobacterium and milk powder in a dry mixer.
18 Screening powder: the granularity of the milk powder is uniform through the vibrating screen, and the powder slag is scrapped.
19 Powder discharge: and (3) receiving powder by using a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room.
20 Powder) is added: and pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.
21 Packaging: nitrogen filling and packaging of automatic packaging machines with different specifications; the oxygen content is lower than 1-5% when nitrogen is filled.
22 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine.
23 Inspection of the finished product: sampling and checking the packaged product according to a checking plan.
24 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
The previous description of the embodiments is provided to facilitate a person of ordinary skill in the art in order to make and use the present invention. It will be apparent to those skilled in the art that various modifications can be readily made to these embodiments and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments, and those skilled in the art, based on the present disclosure, should make improvements and modifications without departing from the scope of the present invention.
Claims (10)
1. A formula, said formula comprising a composition of alpha-lactalbumin, beta-casein and vitamin B2, wherein the mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 is (900-7000): (1100-9000): (0.31-2.4), the alpha-lactalbumin accounts for 9-50% of the total protein content, and the beta-casein accounts for 10.5-60% of the total protein content.
2. Formula according to claim 1, wherein the mass ratio of α -lactalbumin, β -casein and vitamin B2 is (900-5500): (1100-7500): (0.31-2.0), the alpha-lactalbumin accounts for 9-45% of the total protein content, the beta-casein accounts for 10.5-50% of the total protein content,
Preferably, the mass ratio of alpha-lactalbumin, beta-casein and vitamin B2 is (1000-5500): (1100-7500): (0.4-2.0), the alpha-lactalbumin accounts for 10-45% of the total protein content, and the beta-casein accounts for 10.5-56% of the total protein content.
3. A formula according to claim 1 wherein the alpha-lactalbumin is derived from skim milk powder, concentrated whey protein powder, whey protein powder of different alpha-lactalbumin content or other raw materials which provide alpha-lactalbumin;
Preferably, the beta-casein is derived from skim milk powder, casein powder of different beta-casein content or other raw materials capable of providing beta-casein;
preferably, the source of vitamin B2 comprises one or more of riboflavin, riboflavin-5' -sodium phosphate.
4. The formula milk powder according to claim 1, wherein the raw materials further comprise one or a combination of more than two of DHA, ARA, nucleotide and lactoferrin,
Preferably, the raw materials of the formula milk powder based on 1000 parts by weight comprise: 0-15 parts of DHA, 0-25 parts of ARA, 0-1.5 parts of lactoferrin and 0-0.8 part of nucleotide.
5. The formula milk powder according to claim 1, wherein the raw materials further comprise compound nutrients comprising calcium powder, vitamins and minerals,
Preferably, the raw materials of the formula milk powder based on 1000 parts by weight comprise: 7-22 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals;
more preferably, the compound nutrients are added at least in the form of compound vitamin packages, calcium powder and mineral nutrition packages;
Preferably, the compound nutrient is added in the form of a nutritional package:
1) The compound vitamin nutrition package comprises the following components in each gram of compound vitamin nutrition package:
Taurine: 130-220mg of the total weight of the composition,
Vitamin a:1400-2700 mu gRE,
Vitamin D: 30-68. Mu.g of the total,
Vitamin B 1: 1400-3200. Mu.g of the total weight of the composition,
Vitamin B 2: 880-4000. Mu.g of the total amount of the components,
Vitamin B 6: 1040-2800 mug of the total weight of the composition,
Vitamin B 12: 4-10 mu g of the total weight of the medicine,
Vitamin K 1: 150-320. Mu.g of the total,
Vitamin C:145-500 the dosage of the medicine is more than one mg,
Vitamin E:12-50mg of alpha-TE, and,
Nicotinic acid: 10000-23000 mug of the total weight of the composition,
Folic acid: 210-420 mug of the total weight of the product,
Biotin: 30-85 mu g of the total weight of the medicine,
Pantothenic acid: 7100-13800 mug of the powder,
Inositol: 0-250mg of the total amount of the components,
L-carnitine: 0-60mg of the total weight of the composition,
2) The mineral substance-nutrition package comprises the following components in each gram of the mineral substance-nutrition package:
Iron: 45-95mg of the total weight of the composition,
Zinc: 22-78 the dosage of the medicine is more than one mg,
Copper: 2600-4420. Mu.g,
Iodine: 500-1550 mug of the total weight of the product,
Selenium: 0-260. Mu.g of the total weight of the composition,
Manganese: 0-810 mu g of the total weight of the mixture,
3) The mineral substance two-nutrition package comprises the following components in each gram of the mineral substance two-nutrition package:
calcium: 150-345mg of the total weight of the composition,
Phosphorus: 35-150mg of the total weight of the powder,
Sodium: 5-96mg of the extract, wherein the extract is prepared from 5-96mg of the extract,
4) The effective content of magnesium in the magnesium chloride nutrition bag is 10% -16%,
5) The effective content of potassium in the potassium chloride nutrition package is 49% -53%,
6) The choline chloride nutrition packet has the effective content of 72% -76%;
Preferably, based on 1000 weight parts of formula milk powder, the addition amount of the compound vitamin nutrition package is 2 to 4 weight parts, the addition amount of the mineral two nutrition package is 2 to 25 weight parts, the addition amount of the mineral one nutrition package is 0.5 to 3 weight parts, the addition amount of the magnesium chloride nutrition package is 0 to 3.5 weight parts, the addition amount of the potassium chloride nutrition package is 0 to 4.5 weight parts, the addition amount of the choline chloride nutrition is 0 to 2.5 weight parts, and the base material of each nutrition package is preferably lactose or L-sodium ascorbate;
Preferably, the raw materials also comprise probiotics,
Preferably, the probiotic is a bifidobacterium,
Preferably, the bifidobacterium is added in an amount of 0.1 to 0.4 parts by weight, more preferably 0.15 to 0.2 parts by weight,
Preferably, the content of bifidobacteria per part by weight of the bifidobacteria powder is 3X 10 10 CFU or more.
6. The formula of claim 1, wherein the formula is an infant formula, a toddler formula or a child formula.
7. The formula according to any one of claims 1-6, wherein the formula comprises the following raw materials:
8. A method of preparing the formula of any one of claims 1-7, comprising: proportioning, homogenizing, concentrating, sterilizing, spray drying and dry mixing to obtain a finished product;
Preferably, the method comprises:
Mixing milk, powder raw materials and melted oil raw materials after rough filtration and homogenization sterilization, adding galactooligosaccharide syrup into a small hopper, adding a compound nutrition enhancer, a magnesium chloride nutrition package, a potassium chloride nutrition package and a choline chloride nutrition package into a nutrition jar to obtain mixed feed liquid,
Filtering, homogenizing, cooling, concentrating, sterilizing, spray drying, fluidized bed drying, cooling to obtain dry milk powder, mixing with DHA, ARA, lactoferrin, nucleotide and bifidobacterium, and sieving to obtain the formula milk powder;
preferably, the primary pressure of the homogenization treatment of the mixed liquor is 105+/-5 bar, and the secondary pressure is 32+/-3 bar;
Preferably, the concentration sterilization adopts double-effect concentration, more preferably, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds; further preferably, the discharge concentrations are all 48% -52% dry matter;
Preferably, the inlet air temperature of the spray drying is 165-180 ℃, the exhaust air temperature is 75-90 ℃, the pressure of the high-pressure pump is 160-210bar, and the negative pressure of the tower is-4 mbar to-2 mbar;
Preferably, the fluidized bed drying and cooling comprises two times of drying and cooling, and the temperature of the milk powder after the two times of drying and cooling is 25-30 ℃; and mixing phospholipid with carrier, heating to 60-65deg.C, and dispersing on the surface of milk powder under the action of compressed air.
9. Use of a formula according to any one of claims 1 to 7 for the preparation of a product which promotes mineral absorption.
10. Use according to claim 9, wherein said increasing mineral absorption comprises increasing mineral absorption, increasing mineral transporter expression, preferably said mineral transporter comprises TRPV4, OGR1 and/or ZnT1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410335101.8A CN118077774A (en) | 2024-03-22 | 2024-03-22 | Formula milk powder capable of improving mineral absorption and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410335101.8A CN118077774A (en) | 2024-03-22 | 2024-03-22 | Formula milk powder capable of improving mineral absorption and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118077774A true CN118077774A (en) | 2024-05-28 |
Family
ID=91150471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410335101.8A Pending CN118077774A (en) | 2024-03-22 | 2024-03-22 | Formula milk powder capable of improving mineral absorption and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118077774A (en) |
-
2024
- 2024-03-22 CN CN202410335101.8A patent/CN118077774A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107259527B (en) | Nutritional composition | |
| CN102550677B (en) | Liquid dairy product with health-care function on middle and old-aged people and production method for liquid dairy product | |
| CN114568526A (en) | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof | |
| WO2019104390A1 (en) | Milk substitute compositions | |
| CN114223729B (en) | Application of bifidobacterium longum subspecies infantis and breast milk oligosaccharide composition in formula milk powder | |
| CN106605709B (en) | Liquid milk suitable for children of 3-6 years old and preparation method thereof | |
| CN111345358A (en) | Child formula goat milk powder rich in lactophospholipid and preparation method thereof | |
| CN106259938A (en) | Breast milk 0-12 month babies ' formula milk powder containing nucleotide and OPO structured lipid and preparation method thereof | |
| CN105188409A (en) | Infant nutritional product with RRR alpha-tocopherol | |
| CN105558046A (en) | Formula food with special medicinal purpose and suitable for liver disease and preparation method thereof | |
| CN114208893B (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN114128767B (en) | Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides | |
| CN105432792A (en) | Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods | |
| CN113841740A (en) | Sialic acid-containing infant formula milk powder and preparation method thereof | |
| CN114145353A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN107927198A (en) | One kind drinks milk powder and preparation method thereof for premature | |
| CN118077774A (en) | Formula milk powder capable of improving mineral absorption and preparation method thereof | |
| CN114223728B (en) | Premature/low birth weight infant formula containing prebiotics and probiotics | |
| CN116250570A (en) | Infant formula milk powder and preparation method thereof | |
| CN114145356B (en) | Formula milk powder capable of improving immune response and preparation method and application thereof | |
| CN115769840B (en) | Formula milk powder and preparation method thereof | |
| WO2024114729A1 (en) | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof | |
| CN109845826A (en) | A kind of infant milk powder for simulating breast milk fatty acids structure and composition | |
| CN115669732B (en) | Hypoallergenic infant partially hydrolyzed formula containing the breast milk oligosaccharide LNnT | |
| CN115804410A (en) | Infant formula containing prebiotic composition for promoting growth of Bifidobacterium longum subspecies of infants YLGB-1496 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication |